Summary
According to the recently published report 'Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 - Drugs In Development, 2022'; Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Gamma-aminobutyric acid A receptor, alpha 3 or GABRA3 is a protein encoded by the GABRA3 gene. GABRA3 are ligand-gated chloride channels and are activated by the major inhibitory neurotransmitter in the mammalian brain and has been found to mediate anxiolytic activity, which plays a key role in emotional and behavioral control.
The report 'Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 - Drugs In Development, 2022' outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 1 and 1 respectively. Report covers products from therapy areas Central Nervous System, Dermatology and Genito Urinary System And Sex Hormones which include indications Anxiety Disorders, Epilepsy, Neuropathic Pain (Neuralgia), Depression, Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), Fibromyalgia (Fibromyalgia Syndrome), Panic Disorders, Primary Hyperoxaluria, Primary Hyperoxaluria Type I, Primary Hyperoxaluria Type II and Pruritus.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3)
- The report reviews Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Overview
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Companies Involved in Therapeutics Development
Baergic Bio Inc
Biocodex
Cerevel Therapeutics Holdings Inc
Engrail Therapeutics Inc
Saniona AB
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Drug Profiles
BAER-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
darigabat - Drug Profile
Product Description
Mechanism Of Action
History of Events
NCT-10004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SAN-711 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Agonize GABR for Neuropathic Pain and Fibromyalgia - Drug Profile
Product Description
Mechanism Of Action
History of Events
stiripentol - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Dormant Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Discontinued Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Product Development Milestones
Featured News & Press Releases
Mar 24, 2022: Saniona initiates positron emission tomography (PET) stage of SAN711 phase 1 clinical trial
Mar 24, 2022: Saniona initiates positron emission tomography (PET) stage of SAN711 phase 1 clinical trial
Feb 15, 2022: Cerevel Therapeutics announces positive topline results for Darigabat in phase 1 clinical trial in acute anxiety
Feb 10, 2022: Saniona initiates multiple ascending dose stage of SAN711 phase 1 clinical trial
Aug 31, 2021: BioStock: Saniona’s clinical and regulatory progress during H1
Jun 30, 2021: Saniona initiates phase 1 clinical trial of SAN711
Jun 08, 2021: Saniona to present preclinical data on SAN711 at the 7th Congress of the European Academy of Neurology
Jan 28, 2021: Cerevel Therapeutics hosts Inaugural Virtual R&D event to review Darigabat (CVL-865) and provide overview of key preclinical programs
Oct 06, 2020: Cerevel Therapeutics announces first patient dosed in phase 2 trial of CVL-865, an investigational therapy in development for the treatment of Epilepsy
Dec 08, 2019: Cerevel Therapeutics announces phase 1 results for CVL-865, a Novel a2/3/5-subtype GABAA Positive Allosteric Modulator in Development to treat Epilepsy
Nov 25, 2019: Cerevel Therapeutics to present safety, tolerability, and pharmacokinetics results from phase 1 trial of CVL-865
Apr 24, 2019: US Bioservices selected by Biocodex SAS to exclusively dispense DIACOMIT (stiripentol)
Apr 09, 2019: Cerevel Therapeutics announces publication of phase 2a study results in Neurology on its most advanced investigational Epilepsy treatment
Feb 18, 2019: Sanionas SAN711 selected for clinical studies in itching and pain
Feb 13, 2019: NeuroCycle Therapeutics receives NIH SBIR Grant to study Dravet Syndrome drug candidate NCT10004
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Baergic Bio Inc, 2022
Pipeline by Biocodex, 2022
Pipeline by Cerevel Therapeutics Holdings Inc, 2022
Pipeline by Engrail Therapeutics Inc, 2022
Pipeline by Saniona AB, 2022
Dormant Projects, 2022
Discontinued Products, 2022
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
